Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YGYFBY-2
- Development stage
- Preclinical
- Lead developer
- Silver Valley Pharmaceutical
- Modality
- Small Molecules
01
Overview
YGYFBY-2 is a small molecule drug candidate being developed by Silver Valley Pharmaceutical (also known as Yingu Pharmaceutical) for the treatment of anaphylaxis. Anaphylaxis is a severe, potentially life-threatening systemic allergic reaction that occurs suddenly after exposure to an allergen. Currently in the preclinical stage of development, YGYFBY-2 is part of Silver Valley's research pipeline focused on allergic and respiratory conditions. While the specific molecular target and mechanism of action have not been publicly disclosed, the candidate aims to provide a new therapeutic option for managing acute allergic emergencies.
Beyond the preview
Go deeper on YGYFBY-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YGYFBY-2.